RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease.
Increased frequencies of T-helper cells producing the proinflammatory cytokine IL-17A (TH17) have been reported in ankylosing spondylitis (AS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD).1 Genome-wide association studies have linked multiple TH17-assoc...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2015
|
| _version_ | 1797059463828471808 |
|---|---|
| author | de Wit, J Al-Mossawi, M Hühn, M Arancibia-Cárcamo, C Doig, K Kendrick, B Gundle, R Taylor, P Mcclanahan, T Murphy, E Zhang, H Barr, K Miller, J Hu, X Aicher, T Morgan, R Glick, G Zaller, D Correll, C Powrie, F Bowness, P |
| author_facet | de Wit, J Al-Mossawi, M Hühn, M Arancibia-Cárcamo, C Doig, K Kendrick, B Gundle, R Taylor, P Mcclanahan, T Murphy, E Zhang, H Barr, K Miller, J Hu, X Aicher, T Morgan, R Glick, G Zaller, D Correll, C Powrie, F Bowness, P |
| author_sort | de Wit, J |
| collection | OXFORD |
| description | Increased frequencies of T-helper cells producing the proinflammatory cytokine IL-17A (TH17) have been reported in ankylosing spondylitis (AS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD).1 Genome-wide association studies have linked multiple TH17-associated genes, including IL23R, with AS, psoriasis, and IBD, further supporting a common pathogenic role for the IL-17/IL-23 axis in these diseases. 2 Neutralizing IL-17A with mAbs has shown efficacy in AS and PsA,3 and some benefit in RA,4 but has proved ineffective and possibly deleterious in patients with IBD.5 There is therefore a need for new therapies, including small-molecule inhibitors, that target type 17 immune responses. |
| first_indexed | 2024-03-06T20:04:36Z |
| format | Journal article |
| id | oxford-uuid:28828119-f9a6-402b-8b5a-e4ecea65fb7e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:04:36Z |
| publishDate | 2015 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:28828119-f9a6-402b-8b5a-e4ecea65fb7e2022-03-26T12:13:16ZRORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:28828119-f9a6-402b-8b5a-e4ecea65fb7eEnglishSymplectic Elements at OxfordElsevier2015de Wit, JAl-Mossawi, MHühn, MArancibia-Cárcamo, CDoig, KKendrick, BGundle, RTaylor, PMcclanahan, TMurphy, EZhang, HBarr, KMiller, JHu, XAicher, TMorgan, RGlick, GZaller, DCorrell, CPowrie, FBowness, PIncreased frequencies of T-helper cells producing the proinflammatory cytokine IL-17A (TH17) have been reported in ankylosing spondylitis (AS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD).1 Genome-wide association studies have linked multiple TH17-associated genes, including IL23R, with AS, psoriasis, and IBD, further supporting a common pathogenic role for the IL-17/IL-23 axis in these diseases. 2 Neutralizing IL-17A with mAbs has shown efficacy in AS and PsA,3 and some benefit in RA,4 but has proved ineffective and possibly deleterious in patients with IBD.5 There is therefore a need for new therapies, including small-molecule inhibitors, that target type 17 immune responses. |
| spellingShingle | de Wit, J Al-Mossawi, M Hühn, M Arancibia-Cárcamo, C Doig, K Kendrick, B Gundle, R Taylor, P Mcclanahan, T Murphy, E Zhang, H Barr, K Miller, J Hu, X Aicher, T Morgan, R Glick, G Zaller, D Correll, C Powrie, F Bowness, P RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. |
| title | RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. |
| title_full | RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. |
| title_fullStr | RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. |
| title_full_unstemmed | RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. |
| title_short | RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. |
| title_sort | rorγt inhibitors suppress th17 responses in inflammatory arthritis and inflammatory bowel disease |
| work_keys_str_mv | AT dewitj rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT almossawim rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT huhnm rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT arancibiacarcamoc rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT doigk rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT kendrickb rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT gundler rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT taylorp rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT mcclanahant rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT murphye rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT zhangh rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT barrk rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT millerj rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT hux rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT aichert rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT morganr rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT glickg rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT zallerd rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT correllc rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT powrief rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease AT bownessp rorgtinhibitorssuppressth17responsesininflammatoryarthritisandinflammatoryboweldisease |